Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.
about
Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trialEducational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillationEmerging Tools for Stroke Prevention in Atrial FibrillationChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewMinimizing bleeding risk in patients receiving direct oral anticoagulants for stroke preventionSearch For The Ideal Antithrombotic Drug: Utopian Task Likely Is Implemented AlreadyCerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage riskEffect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation.Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital.Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis.Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixabanBleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin.Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study.Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial FibrillationGinkgo and Warfarin Interaction in a Large Veterans Administration PopulationRivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactionsDiagnosis and management of atrial fibrillation by primary care physicians in Italy : a retrospective, observational analysisEffectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.Preserving Cognitive Function in Patients with Atrial FibrillationStroke And Bleeding Risk Assessment: Where Are We Now?Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists.Can we predict stroke in atrial fibrillation?Can we predict the occurrence of atrial fibrillation?2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial designCurrent anticoagulant safety.Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?Oral anticoagulation therapy for elderly patients with atrial fibrillation: utility of bleeding risk covariates to better understand and moderate risks.Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation.Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more).Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force.Management and prognosis of atrial fibrillation in the diabetic patient.Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation.Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.A High HASBLED Score Identifies Poor Warfarin Control in Patients Treated for Non-Valvular Atrial Fibrillation in Australia and Singapore.Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.Cerebral Amyloid Angiopathy in Stroke Medicine.Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation.Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?
P2860
Q21132512-118A1445-1D52-44A1-849C-95B48574BFE2Q24202280-234AE53E-A58B-48A2-9541-61FA70D36BDAQ26765023-41DDDAB8-C491-4D34-BDCF-08C3056D10FBQ26765949-6E516CEB-4BBC-4BA3-A642-36AA6A10F816Q28069809-4C3D2CC4-49B9-45D5-BB18-B2668392E953Q28072644-6B2976BE-3BEC-4C4A-9921-B82A8034C826Q30570918-41610DF4-ECA7-412C-8E31-0A8AE49C64E5Q34233473-69BE24A4-7763-4455-A86E-33EADC8BA765Q35105020-47C21DF3-5DBD-4214-A9B6-55E34C5DF453Q35205072-CF8F5AFC-86B7-4B32-B7A8-C5A60126F9B8Q35609742-55F61696-4BF6-4700-BF8C-29CA0CE6D57BQ35666219-356652E7-AB30-4D36-B660-DA08D45247E7Q36011253-2058175F-A694-4B91-9372-04B62DA76122Q36217719-5BF6DA8F-8484-4F0C-BD33-2316388CB139Q36335405-BE7282F9-D8BE-44D1-9F83-BADFCF1208FBQ36395780-388B3CD2-CAC1-4814-BAB9-01AF9331DB76Q36613264-37AB2699-F4B9-4196-A30B-81174B7AF5B6Q36706825-6ECBD15C-93AE-4468-A29F-52D39BD97627Q36956761-E2A7DCB0-76E5-46A9-9CA1-3EB2D9B5343EQ37222352-962646CA-EC6B-4218-99D5-0ED8330DA4BBQ37468856-4D971AB3-C4E2-4EE9-A343-3E082992078DQ37469069-A63A0595-550F-48E5-AFCD-FF055AB2648FQ37624211-1C2566C5-C4DB-484C-AAF9-3FC8D10C7AC3Q37975986-0480FB1A-035D-405F-88A0-D9288F4EEFC0Q37975988-048A2F12-1EDA-47E0-A5C7-CF75595948BAQ37989837-A1894453-84B4-4676-8201-EF3B6D9E5109Q37990564-21CB3311-3ADF-4F84-A2A2-59A3A77705B5Q38067326-2E16A916-6BC1-4AC2-9A6E-56D241B48544Q38113554-E8897D90-560F-494E-92C2-958077F9758FQ38164313-51F27CC2-EF29-4BA3-82FE-756F8F0A417EQ38244278-493C2242-7CE9-49AA-B599-075F0E6D198EQ38244795-EFF12BA8-FE28-46B1-8760-90DE054C5F2DQ38497702-D9A71D0E-2B6D-4990-BE6E-0E17D0AEC165Q38671522-347D950A-A8FF-4871-A6B4-361125285CF7Q38712351-7407BD89-1047-411E-B313-0D23FB1E5C4DQ38714422-E20E62F4-FC41-4437-8143-57BDF351DD6BQ38902990-658F3767-6180-4417-9C35-2BF932ADEA23Q39126853-3A5C24EC-A7EF-4CFD-96A4-E8D439AF80B7Q40872628-4B3C1F37-FB39-4866-80F2-7A32AD563352Q41857087-84B47EFB-25AD-4AAE-A9B9-E2BCF42DE2F1
P2860
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bleeding risk assessment and m ...... y Working Group on Thrombosis.
@en
Bleeding risk assessment and m ...... y Working Group on Thrombosis.
@nl
type
label
Bleeding risk assessment and m ...... y Working Group on Thrombosis.
@en
Bleeding risk assessment and m ...... y Working Group on Thrombosis.
@nl
prefLabel
Bleeding risk assessment and m ...... y Working Group on Thrombosis.
@en
Bleeding risk assessment and m ...... y Working Group on Thrombosis.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Bleeding risk assessment and m ...... y Working Group on Thrombosis.
@en
P2093
Andrea Rubboli
Daniela Poli
Deirdre A Lane
Document reviewers:
Eve Knight
Felicita Andreotti
Francisco Marin
Gualtiero Palareti
Jean-Philippe Collet
P2860
P304
P356
10.1093/EUROPACE/EUR126
P577
2011-05-01T00:00:00Z